Molbio DiagnosticsIPO Review — Financials, Valuation & Peers
A data-only look at the Molbio Diagnostics IPO: restated financials, valuation ratios, the RHP peer group and third-party analyst views. ipostation does not rate IPOs — nothing here is a recommendation.
Financials (₹ Cr)
| Period Ended | Revenue | PAT | EBITDA | Net Worth | Total Assets | Borrowings | EPS (₹) |
|---|---|---|---|---|---|---|---|
| FY 2024 | 840.66 | 83.54 | 185.09 | 807.94 | 1,221.06 | 174.58 | — |
| FY 2025 | 1,027.94 | 138.58 | 256.64 | 952.95 | 1,461.56 | 123.16 | — |
| FY 2026 | 1,455.17 | 164.14 | 328.24 | 1,144.68 | 2,148.42 | 412.64 | 14.56 |
Restated figures from the offer document. Amounts in ₹ crore; EPS in ₹ per share. FY = the 12 months ended 31 March.
KPIs & Valuation
- P/E (pre-issue)
- 55.43x
- P/E (post-issue)
- 56.67x
- RoNW
- 14.55%
- RoE
- 15.59%
- RoCE
- 17.55%
- EPS (pre-issue)
- ₹14.56
- EPS (post-issue)
- ₹14.24
- EBITDA Margin
- 22.56%
- PAT Margin
- 11.28%
- P/BV
- 9.55x
- NAV / share
- ₹101.51
- Market Cap
- ₹9,299.87 Cr
As of 31 Mar 2026 (latest reported period in the offer document). Market cap is computed on a post-issue basis at the upper price band.
Peer Comparison
| Company | EPS (₹) | NAV (₹) | P/E | RoNW | Statements |
|---|---|---|---|---|---|
| Molbio Diagnostics | 14.77 | 101.51 | — | 14.55% | Restated |
| Dr. Lal Pathlabs Ltd | 30.24 | 145 | 62.2x | 20.78% | Consolidated |
| Metropolis Healthcare Ltd | 9.19 | 72.98 | 63.72x | 12.56% | Consolidated |
| Poly Medicure Ltd | 31.79 | 306.45 | 52.61x | 10.37% | Consolidated |
| Vijaya Diagnostic Centre Ltd | 16.81 | 93.02 | 81.02x | 18.07% | Consolidated |
Peer group as disclosed in the offer document, figures as of 31 Mar 2026. The issuer’s P/E is computed at the upper price band.
Promoters & Shareholding
Promoters: <p>Sriram Natarajan, Chandrasekhar Bhaskaran Nair, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram, Exxora Trading LLP</p>
- Holding (pre-issue)
- 44.89%
- Holding (post-issue)
- 41.29%
- Dilution
- 3.6%
Broker Recommendations
| Reviewer | Verdict |
|---|---|
| Capital Market | May Apply |
Third-party analyst views on the Molbio Diagnostics IPO, aggregated for reference. ipostation does not rate IPOs — nothing here is investment advice.
Analysis in brief
Anchor book
Before the issue opened to the public, Molbio Diagnostics placed shares with 33 anchor investors, who together put in ₹281.45 crore. Anchor investors are institutions allotted shares at the issue price a day before bidding opens, in exchange for a mandatory post-listing lock-in — their names and cheque sizes are disclosed, which is why the anchor book is read as an institutional signal. The largest allocations went to GOLDMAN SACHS FUNDS-GOLDMAN SACHS INDIA EQUITY PORTFOLIO (₹25 crore), MIRAE ASSET HEALTHCARE FUND (₹20 crore) and BLACKROCK GLOBAL FUNDS-INDIA FUND (₹20 crore). Investor categories represented include Other, FII/FPI and Insurance. The lock-in on half the anchor shares ends on 11 Sept 2026, with the remainder locked until 10 Nov 2026.
Analyst view tally
1 third-party review is on record for the Molbio Diagnostics IPO — among them Capital Market. Of the 1 with a stated verdict, 1 says "May Apply". These are the views of the named reviewers, reproduced as published — they are not ipostation's recommendation, and this page does not rate the issue.
Margin and return profile
Beyond the headline pricing, the disclosed operating profile stands on its own numbers. Molbio Diagnostics operates at an EBITDA margin of 22.56% and a net (PAT) margin of 11.28% — the share of revenue retained at the operating and the net level respectively. Capital efficiency reads at a return on capital employed (RoCE) of 17.55% and a return on equity (RoE) of 15.59%. At the upper band, the post-issue market capitalisation works out to about ₹9,299.87 crore. These are offer-document figures for the latest reported period (as of 31 Mar 2026); they describe the business as disclosed, not how the stock will trade.
Objects of the issue
Per the offer document, the company intends to deploy the net proceeds primarily toward funding capital expenditure towards the setting up of infrastructure for research and development facility, center of excellence and connected office space. (₹105.54 crore), alongside funding capital expenditure towards the purchase of certain plant, machinery and other equipment for goa unit i, goa unit ii and visakhapatnam unit, and (₹72.28 crore). In all, 4 objects are disclosed.
Financials
In FY2026, Molbio Diagnostics reported revenue of ₹1,455.17 crore and a net profit of ₹164.14 crore. Revenue grew from ₹840.66 crore in FY2024 to ₹1,455.17 crore in FY2026 (+73.0%). Net worth stood at ₹1,144.68 crore at the end of FY2026. At the upper band, that puts the issue at roughly 55.4× FY2026 earnings (P/E), a figure worth comparing against listed peers in the sector.
Valuation
At the upper band, the issue is priced at 56.67× post-issue earnings and 9.55× book value, against a return on net worth of 14.55%. These ratios come from the offer document and are for comparison, not a recommendation.
Peer comparison
The offer document names listed peers including Dr. Lal Pathlabs Ltd and Metropolis Healthcare Ltd, with a median peer P/E of about 63×. The issue's own post-issue P/E works out to 56.67×.
Promoters
The promoters of the company are <p>Sriram Natarajan, Chandrasekhar Bhaskaran Nair, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram, Exxora Trading LLP</p>. Promoter holding stands at 44.89% before the issue and comes down to 41.29% after listing.
Frequently asked questions
- What is the reservation split in the Molbio Diagnostics IPO?
- Of the total shares offered, retail investors get 34.94%, QIBs 19.96% (plus 29.95% anchor), non-institutional investors 14.97%.
- Who are the promoters of Molbio Diagnostics and what is their holding?
- The promoters are <p>Sriram Natarajan, Chandrasekhar Bhaskaran Nair, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram, Exxora Trading LLP</p>. Promoter holding is 44.89% before the issue and 41.29% after listing.
- What is the P/E ratio of the Molbio Diagnostics IPO?
- At the upper price band, the Molbio Diagnostics IPO is valued at 55.43× pre-issue earnings and 56.67× post-issue earnings, based on the financials disclosed in the offer document.
- What are the objects of the Molbio Diagnostics IPO?
- The net proceeds go primarily toward funding capital expenditure towards the setting up of infrastructure for research and development facility, center of excellence and connected office space., among 4 disclosed objects.